Peginterferon alfa-2a (40KD) plus 800 or 1000/1200 mg/day ribavirin in genotype 1 HIV–HCV co-infected patients: early responses to treatment and predictability for SVR in the PARADIGM study

Rodriguez-Torres, MSlim, JBhatti, LSterling, RHassanein, TClotet, BBranco, TBertasso, AStancic, SSulkowski, M2011-03-102011-03-102010In: INTERNATIONAL LIVER CONGRESS. Annual Meeting of the European Association for the Study of the Liver, 45, Vienna, 14-18 April, 2010http://hdl.handle.net/10400.10/304otherPeginterferão alfa-2aPeginterferon alfa-2aRibavirinaRibavirinInfecção por HIVHIV infectionsHepatite CHepatitis CPARADIGM studyPeginterferon alfa-2a (40KD) plus 800 or 1000/1200 mg/day ribavirin in genotype 1 HIV–HCV co-infected patients: early responses to treatment and predictability for SVR in the PARADIGM studyconference object